Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Avvio Medical
- Study ID
- NCT06942949
- Status
- Recruiting
Conditions
- Kidney Calculi; Ureteral Calculi
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ELS (Enhanced Lithotripsy System) — DEVICEELS (Enhanced Lithotripsy System) utilizes low pressure ultrasound to actuate proprietary microbubbles administered into the urine to pit and fragment urinary stones.
Study Details
The purpose of this study is to evaluate the safety and performance of the ELS to treat urinary stones. The ELS is intended to break urinary stones into small fragments that can pass during or after the procedure with less or no discomfort. Eligible patients are male or females, age 21 or older, with a single urinary stone in the ureter. Participants will undergo the ELS procedure and then be evaluated 30 days later for the presence or absence of urinary stone fragments on a CT scan. Subjects who still have stone present at Day 30 will be evaluated again at Day 60. Other outcome measures will be changes in pain, quality of life, and return to normal daily activities/work.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Apr 2025
- Primary completion
- May 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 101 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: The ELS Trial is a prospective, multi-center, single arm study.All Subjects who qualify to participate in the ELS Trial will receive the experimental ELS procedure.
Primary Outcome Measure
Primary Outcome Measure [ Time Frame: From ELS treatment to 30 Days afterward. ]
Central Contacts
- Louis Marcoux415-887-2037
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona State Urological Research Institute | Phoenix | Arizona | 85225 | Clinical Research Coordinator 602-842-5305 Pratik Patel, MD (PRINCIPAL_INVESTIGATOR) |
| Michael G. Oefelein Clinical Trials | Bakersfield | California | 93301 | Michael Oefelein, MD (PRINCIPAL_INVESTIGATOR) |
| San Diego Clinical Trials | La Mesa | California | 91942 | Mohamed Bidair, MD (PRINCIPAL_INVESTIGATOR) |
| Golden State Urology | Sacramento | California | 95823 | Prithipal Sethi, MD (PRINCIPAL_INVESTIGATOR) |
| University of Miami Hospital | Miami | Florida | 33136 | Hemendra Shah, MD (PRINCIPAL_INVESTIGATOR) |
| Georgia Urology | Roswell | Georgia | 300076 | Adam Mellis, MD (PRINCIPAL_INVESTIGATOR) |
| Comprehensive Urologic Care | Lake Barrington | Illinois | 60010 | Ning Wu, MD (PRINCIPAL_INVESTIGATOR) |
| Wichita Urology Group | Wichita | Kansas | 67226 | Timothy Richardson, MD (PRINCIPAL_INVESTIGATOR) |
| Minnesota Urology | Woodbury | Minnesota | 55125 | Aaron Milbank, MD (PRINCIPAL_INVESTIGATOR) |
| University of Rochester Medical Center | Rochester | New York | 14620 | Rajat Jain, MD (PRINCIPAL_INVESTIGATOR) |
| SUNY - Upstate Medical University | Syracuse | New York | 13210 | Scott Wiener, MD (PRINCIPAL_INVESTIGATOR) |
| Duke | Durham | North Carolina | 27710 | Robert Medairos, MD (PRINCIPAL_INVESTIGATOR) |
| Urology San Antonio | San Antonio | Texas | 78229 | Matthias Hofer, MD (PRINCIPAL_INVESTIGATOR) |
| University of Virginia | Charlottesville | Virginia | 22903 | Wesley Pate, MD (PRINCIPAL_INVESTIGATOR) |
| University of Virginia Community Health | Culpeper | Virginia | 22701 | Gregg Eure, MD (PRINCIPAL_INVESTIGATOR) |
| Urology of Virginia | Virginia Beach | Virginia | 23462 | James Young, MD (PRINCIPAL_INVESTIGATOR) |